The purpose of this letter is to address incorrect statements contained in the article by Dr Halliday entitled 'Surfactants: past, present, and future,' published in a supplement of the May 2008 issue of the Journal of Perinatology. 1 The statements concern lucinactant, a peptide-containing synthetic surfactant currently under review by the United States Food and Drug Administration (US FDA), and clinical trials involving lucinactant that were mentioned in the article.
Dr Halliday states in his article that lucinactant is a gel at both room and body temperature, and that it needs to be heated to 44 1C in a water bath. Lucinactant, like the surfactants that are currently available in the US, requires refrigeration for transport and storage prior to use. At refrigeration temperatures of 2-8 1C lucinactant is in a gel state, but becomes a free flowing liquid after warming to 20-25 and 37 1C. In clinical trials, a dry block heater, referred to as a warming cradle, 2,3 was used to warm the lucinactant. A water bath was not recommended, and if used during a clinical trial would have been considered a protocol violation. The dry block heater temperature was set at 44 1C and the lucinactant vials were placed in the dry block heater for 15 min, as summarized in the published reports of the lucinactant trials. 2, 3 This procedure avoids imprecision around warming methods using body heat or exposure to room temperatures that may range from 20-25 1C and assures that each dose of surfactant is prepared in an identical way. When warmed for 15 min in a dry block heater set at 44 1C, lucinactant reaches a temperature that approximates body temperature. It is important to note that it is neither necessary nor recommended to heat lucinactant so that it reaches a temperature of 44 1C.
When the clinical trials involving lucinactant were described in the article, it was stated that one trial was conducted mainly in South America and that the other trial had many babies recruited from Poland. The Safety and Effectiveness of Lucinactant versus Exosurf in a Clinical Trial of RDS in premature infants (SELECT) study included sites located in South America, but these sites made up less than a third of the total sites used in the study. 2 In addition, the adjudication committee and the data safety monitoring board were both based in the US. Similarly, the Surfaxin Therapy Against Respiratory distress syndrome (STAR) study included sites in Poland, but these sites made up less than a quarter of the total study sites, 3 and the two top enrolling sites were outside of Poland. If a summary statement of the study site locations is relevant, the most accurate description of study site locations is Europe and Latin America for the SELECT study and Europe and the Americas for the STAR study.
In addition, Dr Halliday noted that surfactants in the STAR trial were administered within 30 min and therefore did not reflect conventional prophylaxis. According to the American Academy of Pediatrics Guidance for the Clinician in Rendering Pediatric Care, prophylactic surfactant replacement therapy should be administered between 10 and 30 min after birth. 4 Therefore, treatment in the STAR trial does reflect conventional prophylaxis in the United States. Finally, it was stated that the STAR trial was terminated early due to a lack of financial support and diversion of resources. As stated in the published report, slow enrollment and the futility of attaining full enrollment triggered the study termination. 3 The decision to stop the trial was not influenced by the diversion of financial support to another trial. Dr Halliday concludes that synthetic surfactants are probably not yet ready for the market. As we wait for the official answer to this question from the FDA, it is important to ensure that information regarding emerging products is factual and accurate.
